Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

NCT03828448 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

34

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic/Business Decision

Conditions

Follicular Lymphoma
Small Lymphocytic Lymphoma

Interventions

DRUG: Ublituximab
DRUG: Umbralisib

Sponsor

TG Therapeutics, Inc.